Positron Corporation

Positron Corporation Announces Attrius® PET System Sale

Retrieved on: 
Friday, November 24, 2023
Molecular imaging, Physician, PET, Hospital, POSC, Positron Corporation, SPECT, Positron, OTC, Medical imaging

Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in Pennsylvania as a new customer utilizing Positron’s Attrius® PET System and services.

Key Points: 
  • Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in Pennsylvania as a new customer utilizing Positron’s Attrius® PET System and services.
  • Positron is the only company in the industry offering a dedicated PET scanner optimized for nuclear cardiology.
  • Adel Abdullah, President of Positron stated, “We are pleased to be part of our customers evolution from SPECT to cardiac PET imaging.
  • Positron’s Attrius dedicated PET system and services provides nuclear imaging practices the best value through the combination of high technology and  cost-effective imaging solutions.

Positron Corporation Announces Attrius® PET System Sale

Retrieved on: 
Wednesday, October 4, 2023
POSC, Positron Corporation, Positron, PET, Eastman Kodak Co. v. Image Technical Services, Inc., SPECT, Hospital, Physician, Molecular imaging, OTC, Medical imaging

Niagara Falls, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in California as a new customer utilizing Positron’s Attrius® PET System and services.

Key Points: 
  • Niagara Falls, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in California as a new customer utilizing Positron’s Attrius® PET System and services.
  • Positron is the only company in the industry offering a dedicated PET scanner optimized for nuclear cardiology.
  • This transaction is the introduction of the Company’s PET Lease to Own & Services Program, where customers pay one price for a complete package which includes an Attrius PET System and the full scope Clinical & Technical Services.
  • This Program has zero upfront capex expense which provides a most viable operational model for nuclear imaging PET practices seeking the PET modality.

Positron Corporation Announces Start of Clinical Study of Affinity PET-CT Device

Retrieved on: 
Friday, September 8, 2023
Ochsner Health System, Institutional review board, Federal Food, Drug, and Cosmetic Act, Investigational device exemption, POSC, International Committee for the Nanking Safety Zone, Molecular imaging, Positron Corporation, Trial of the century, Register, Documentation, Patient, Physician, OTC, Affinity, FDA, Medical imaging, Positron

Niagara Falls, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity™ PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA.

Key Points: 
  • Niagara Falls, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity™ PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA.
  • The objective of the clinical study is to obtain key data that will represent the performance and efficacy of Positron’s new state-of-the-art PET-CT imaging device.
  • The initial phase of the clinical study will consist of phantom testing and subsequent imaging of human patients once Positron receives its Investigational Device Exemption from the FDA.
  • In parallel with the clinical study Positron will submit its 510k and Registration to the FDA for clearance to market and sell the Affinity PET-CT.

Positron Corporation Orders Six Attrius® PET Systems and Components from Neusoft Positron Medical Systems

Retrieved on: 
Monday, July 31, 2023
POSC, Positron Corporation, Positron, PET, Eastman Kodak Co. v. Image Technical Services, Inc., PET-CT, Hospital, Patient, Physician, Molecular imaging, OTC, Growth, Medical imaging

Niagara Falls, NY, July 31, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company that manufactures, sells and services PET imaging systems and clinical services, is pleased to announce that in combination with its new Business Cooperative Partnership with Shenyang Intelligent Neuclear Medical Technology Co, a wholly owned subsidiary of Neusoft Medical Systems, Positron has agreed on terms to purchase the current inventory from the Company’s PET Joint Venture partner, Neusoft Positron Medical Systems.

Key Points: 
  • Niagara Falls, NY, July 31, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company that manufactures, sells and services PET imaging systems and clinical services, is pleased to announce that in combination with its new Business Cooperative Partnership with Shenyang Intelligent Neuclear Medical Technology Co, a wholly owned subsidiary of Neusoft Medical Systems, Positron has agreed on terms to purchase the current inventory from the Company’s PET Joint Venture partner, Neusoft Positron Medical Systems.
  • Positron will acquire six (6) Attrius PET systems and all Attrius PET system components held in inventory, with an estimated value of $6 million dollars.
  • The Attrius components inventory provides a full spectrum of parts which will service Attrius PET customers over the next decade.
  • Positron has identified multiple nuclear cardiology practices seeking to purchase Attrius  dedicated PET only systems with several sales proposals currently in the process of acceptance.

Positron Corporation Enters New Manufacturing & Components Supplier Cooperative with Neusoft Medical Systems Subsidiary for New PET-CT Device

Retrieved on: 
Friday, July 21, 2023
Federal Food, Drug, and Cosmetic Act, Communication, POSC, Classification, Positron Corporation, Atakent (business cooperation center), PET-CT, Engineering, Molecular imaging, OTC, Affinity, FDA, LTD, Medical imaging, Positron, Neusoft

Niagara Falls, NY, July 21, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company has entered an Novation Agreement with Shenyang Intelligent Neuclear Medical Technology Co, LTD (Intelligent Neuclear Medical), a wholly owned subsidiary of Neusoft Medical Systems (Neusoft), that transfers the original Business Cooperation Agreement between Positron and Neusoft Medical Systems (“Neusoft”) to now include Neusoft’s subsidiary, Intelligent Neuclear Medical.

Key Points: 
  • Niagara Falls, NY, July 21, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company has entered an Novation Agreement with Shenyang Intelligent Neuclear Medical Technology Co, LTD (Intelligent Neuclear Medical), a wholly owned subsidiary of Neusoft Medical Systems (Neusoft), that transfers the original Business Cooperation Agreement between Positron and Neusoft Medical Systems (“Neusoft”) to now include Neusoft’s subsidiary, Intelligent Neuclear Medical.
  • Positron has expanded its role as manufacturer with Intelligent Neuclear Medical designated as the Company’s contracted components supplier.
  • Positron’s classification as the device manufacturer is significant as it will register with the FDA as the applicant  of its FDA 510k submission for Medical Device Clearance for its Affinity PET-CT imaging device.
  • Neusoft formed Intelligent Neuclear Medical as a wholly owned subsidiary to segregate all Neusoft’s current nuclear projects and products, which also includes all nuclear R&D technology initiatives.

Positron Corporation Enters into Agreement with Ochsner Clinic Foundation for Clinical Study of its New “Affinity PET-CT 4D” Device

Retrieved on: 
Wednesday, March 1, 2023
Clinical trial, Cardiology, Clinical, Safety, Certification, International Committee for the Nanking Safety Zone, Affinity, IDE, Molecular imaging, Ochsner Health System, OTC, Institutional review board, FDA, Trial of the century, IRB, PMA, POSC, PET, Federal Food, Drug, and Cosmetic Act, Biomedical Research, Positron Corporation, Medical imaging, Positron

All procedures and participants for the clinical study have been evaluated and approved as required by an independent Institutional Review Board (IRB).

Key Points: 
  • All procedures and participants for the clinical study have been evaluated and approved as required by an independent Institutional Review Board (IRB).
  • Acceptance of the clinical study by the IRB allows Positron to obtain an Investigational Device Exemption (IDE) which is required to collect safety and efficacy data for Positron’s new PET-CT device.
  • The clinical study will be registered in accordance with the requirements of the International Committee of Medical Journal Editors.
  • Positron expects completion of its clinical study and FDA Certification within the next 60 days.

Positron Corporation Announces Plans for Clinical Study of its New “Affinity PET-CT 4D” Nuclear Imaging Device

Retrieved on: 
Tuesday, December 20, 2022
Ochsner Health System, Institutional review board, Cardiology, Record, GCP, Ochsner, Good, Trial of the century, Patient, Nuclear medicine, Molecular imaging, OTC, Certification, FDA, POSC, IRB, Positron Corporation, Biomedical Research, Affinity, Medical imaging, Positron

The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health.

Key Points: 
  • The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health.
  • Dr. Bober has furnished a plan for the clinical study to an Institutional Review Board (IRB), which reviews and monitors biomedical research involving human subjects in accordance with FDA regulations.
  • Performing such an extensive clinical study requires a comprehensive investigational plan, patient selection criteria, labeling, and monitoring with records and reports which adhere to Good Clinical Practices (GCP).
  • The study will provide empirical data necessary for proper representation of the system’s image quality, performance, and efficacy with  cardiac PET imaging agents.

Positron Corporation Announces First Step in Validation of its New PET-CT Device

Retrieved on: 
Tuesday, August 16, 2022
FDA, Securities Act of 1933, GLOBE, Technology, Private Securities Litigation Reform Act, Growth, Securities Exchange Act of 1934, PET/CT, Positron emission tomography, Coronary artery disease, Company, PET, Nuclear medicine, POSC, OTC, K, Positron Corporation, Medicine, FOR, Adoption, Medical imaging, Positron

This important milestone marks the beginning of the most critical step in the launch of Positrons Affinity PET-CT nuclear imaging device.

Key Points: 
  • This important milestone marks the beginning of the most critical step in the launch of Positrons Affinity PET-CT nuclear imaging device.
  • About Positron: Positron Corporation is a nuclear medicine PET imaging device company specializing in the field of cardiac Positron Emission Tomography imaging - the gold standard in cardiac diagnostics.
  • Positron will soon offer a state-of-the-art PET/CT imaging device that will enable nuclear cardiologists to utilize the full power of nuclear imaging.
  • This same PET/CT device allows Positron to address and meet the needs and demand of the vast oncology diagnostics marketplace.

Positron Emission Tomography Market is Anticipated to Progress at a CAGR of 6.92%, Assesses DelveInsight

Retrieved on: 
Thursday, March 31, 2022
CAGR, Application, Control, Bruker, Prostate cancer, Cardiology, Google Images, Neurology, Population, USD, PerkinElmer, Diagnosis, Magnetic resonance imaging, General Electric Company, CT, Tissue, Solution, Ageing, CT scan, Positron emission tomography, Brain tumor, Growth, Type, Partial, Reflection, Awareness, Magnetic resonance, PET, Cell, Positron Corporation, Anomaly, LAS, Breast, PET-CT, PSMA, Cancer, Prevalence, Shimadzu, COVID-19, Degenerative disease, MRI, Breast cancer, Canon Medical Systems Corporation, Alzheimer's disease, Hospital, Medical imaging, Epilepsy

LAS VEGAS, March 31, 2022 /PRNewswire/ -- DelveInsight's Positron Emission Tomography Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Positron Emission Tomography companies in the market.

Key Points: 
  • LAS VEGAS, March 31, 2022 /PRNewswire/ -- DelveInsight's Positron Emission Tomography Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Positron Emission Tomography companies in the market.
  • Positron emission tomography uses a radioactive substance positron emission tomography tracer, a specific positron emission tomography camera, and a computer to show both normal and abnormal metabolic activity.
  • The Positron Emission Tomography images are frequently combined with CT or MRI to provide PET-CT (Positron Emission Tomography Computed Tomography) or PET-MRI scans.
  • To know more about why North America is leading the market growth in the Positron Emission Tomography market, get a snapshot of the report Global Positron Emission Tomography Market Outlook
    The Positron Emission Tomography market is witnessing increased product demand for a variety of reasons.

Positron Emission Tomography Market is Anticipated to Progress at a CAGR of 6.92%, Assesses DelveInsight

Retrieved on: 
Thursday, March 31, 2022
CAGR, Application, Control, Bruker, Prostate cancer, Cardiology, Google Images, Neurology, Population, USD, PerkinElmer, Diagnosis, Magnetic resonance imaging, General Electric Company, CT, Tissue, Solution, Ageing, CT scan, Positron emission tomography, Brain tumor, Growth, Type, Partial, Reflection, Awareness, Magnetic resonance, PET, Cell, Positron Corporation, Anomaly, LAS, Breast, PET-CT, PSMA, Cancer, Prevalence, Shimadzu, COVID-19, Degenerative disease, MRI, Breast cancer, Canon Medical Systems Corporation, Alzheimer's disease, Hospital, Medical imaging, Epilepsy

LAS VEGAS, March 31, 2022 /PRNewswire/ -- DelveInsight's Positron Emission Tomography Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Positron Emission Tomography companies in the market.

Key Points: 
  • LAS VEGAS, March 31, 2022 /PRNewswire/ -- DelveInsight's Positron Emission Tomography Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Positron Emission Tomography companies in the market.
  • Positron emission tomography uses a radioactive substance positron emission tomography tracer, a specific positron emission tomography camera, and a computer to show both normal and abnormal metabolic activity.
  • The Positron Emission Tomography images are frequently combined with CT or MRI to provide PET-CT (Positron Emission Tomography Computed Tomography) or PET-MRI scans.
  • To know more about why North America is leading the market growth in the Positron Emission Tomography market, get a snapshot of the report Global Positron Emission Tomography Market Outlook
    The Positron Emission Tomography market is witnessing increased product demand for a variety of reasons.